Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Infinity Pharmaceuticals expands Phase II lung cancer trial
The study is designed to evaluate IPI-504 as a monotherapy in patients with stage IIIb/IV non-small cell lung cancer (NSCLC) whose tumors have relapsed or become refractory to
The study is designed to evaluate IPI-504 as a monotherapy in patients with stage IIIb/IV non-small cell lung cancer (NSCLC) whose tumors have relapsed or become refractory to
Under the terms of the agreement, Merck Serono will provide Lpath up to $23 million of upfront payments and R&D funding to support Lpath’s completion of the Phase
The product will be marketed under store brand labels and is comparable to Wyeth consumer healthcare’s Advil PM tablets, 200/38mg, indicated as a pain reliever or nighttime sleep-aid.
The agreement provides Ultra Ultrasonik with the rights to sell in Turkey and includes minimum purchase requirements. The SonaStar is used by neuro and general surgeons for quick
The first new type of blood pressure medicine in over a decade Rasilez, known as Tekturna in the US, provides effective blood pressure lowering that lasts beyond 24
The two-arm, randomized, multi-dose, double-blind, placebo-controlled study included Rhinocort as the steroid comparator arm. A secondary efficacy endpoint of this study was the effect of MRX-4 on inflammatory
The collaboration facilitates interactions between physicians and scientists in both organizations to combine resources and expertise in disease intervention whilst providing flexibility to work in a variety of
Under the terms of the agreement, Allergan will pay Spectrum $41.5 million at closing and will make additional payments of up to $304 million based on the achievement
Osteotech has received 510(k) clearance for this material as a bone graft substitute, and as a bone void filler, for use in the spine, pelvis and extremities. Sam
The approval of Apidra for pediatric use is based upon FDA review of a 26-week, Phase III, open-label, active control study of Apidra in comparison with insulin lispro,